About 200 reports

  • MUSCULOSKELETAL DISORDERS THERAPEUTICS MARKET IN AMERICAS
  • MUSCULOSKELETAL DISORDERS THERAPEUTICS MARKET IN EMEA

It develops therapies for musculoskeletal disorders.

  • Musculoskeletal Disorder
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly & Co.
  • Canada Prevalence of Musculoskeletal Disorders
  • Prevalence of Musculoskeletal Disorders in

Change in the muscles, joints, and bones leads to various type of musculoskeletal disorders in old age.

  • Musculoskeletal Disorder
  • World
  • Market Size
  • Baxter International Inc.
  • Gilead Sciences, Inc.
  • MUSCULOSKELETAL DISORDERS MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
  • 9.6.2 Musculoskeletal Disorders Market Revenue and Forecast to 2027 (US$ Mn)

For instance, musculoskeletal disorders represents one of the major public health problems among workers and the general population, and it is multifactorial in origin.

  • Musculoskeletal Disorder
  • World
  • Forecast
  • Market Size
  • Bayer AG
  • MUSCULOSKELETAL DISORDERS DRUGS
  • GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, SEGMENTATION BY SUBSEGMENT

FIGURE ##: GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, SEGMENTATION BY SUBSEGMENT GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY SUBSEGMENT P A G E | ## ## Drugs for Rheumatoid Arthritis was the largest subsegment in the musculoskeletal drugs

  • Musculoskeletal Disorder
  • Market Size
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

SUMMARY: - Musculoskeletal Disorders Pipeline by Indication - Musculoskeletal Disorders Pipeline by Clinical Trial Phase - Musculoskeletal Disorders Pipeline by Drug Mechanism Classes - Musculoskeletal Disorders Pipeline by Comp

  • Chronic Disease
  • Musculoskeletal Disorder
  • Pathology
  • World
  • Market Description
  • Musculoskeletal Drugs Market Forecast Growth
  • Musculoskeletal Drugs Market Historic Growth

Figure ##: Global Musculoskeletal Drugs Market, Historic Market Size, 2013-2017, $ Billion P A G E | ## The global Musculoskeletal Disorders Drugs market grew from $##. ## billion in 2013 to $##. ## billion in 2017 at a compound annual growth rate (CAGR) of ##. ##%.

  • Musculoskeletal Disorder
  • Company Financials
  • Forecast
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • 4.5 IMPACT ANALYSIS
  • GLOBAL MUSCULOSKELETAL DISEASES TREATMENT MARKET - REVENUE FORECASTS AND ANALYSIS -

Musculoskeletal disorders represents one of the major public health problems among workers and the general population, and it is multifactorial in origin.

  • Musculoskeletal Disorder
  • World
  • Forecast
  • Market Size
  • Hitachi, Ltd.
  • 2. Global Foot & Ankle Device Market - Key Takeaways

Musculoskeletal disorders have cost a large amount of healthcare expenditure.

  • Musculoskeletal Disorder
  • World
  • Forecast
  • Market Size
  • Zimmer Biomet Holdings, Inc.

Moreover, the number of surgeries are expected to be rising to the musculoskeletal disorders that are associated with sports, occupational injuries and age-related dysfunction.

  • Musculoskeletal Disorder
  • World
  • Forecast
  • Market Size
  • Bauerfeind AG

Therapeutic Advances in Musculoskeletal Disease; ##(##): ##-## Masi L, et al. (2008).

  • Clinical Trial
  • Musculoskeletal Disorder
  • Therapy
  • Market Size
  • Amgen Inc.
  • 5.1.6 Growing Diabetic Population
  • 5.1.4 Rising Urban Population

Shoulder pain is probably the most common musculoskeletal disorder associated with diabetes.

  • Musculoskeletal Disorder
  • World
  • DJO
  • Johnson & Johnson
  • Zimmer Biomet Holdings, Inc.

Zimmer Biomet is one of the global leaders in musculoskeletal healthcare.

  • Musculoskeletal Disorder
  • Arthrex, Inc.
  • DePuy Orthopaedics, Inc.
  • EmCyte Corporation
  • Synthes, Inc.

Wyeth has a long history of pioneering developments in pharmaceuticals and biotechnology, with leading products in the areas of women' s health care, neuroscience, musculoskeletal disorders, vaccines and infectious disease, hemophilia, and oncology.

  • Musculoskeletal Disorder
  • China
  • Bayer AG
  • Novartis AG
  • Pfizer Inc.

Wyeth has a long history of pioneering developments in pharmaceuticals and biotechnology, with leading products in the areas of women' s health care, neuroscience, musculoskeletal disorders, vaccines and infectious disease, hemophilia, and oncology.

  • Musculoskeletal Disorder
  • China
  • Demand
  • Bayer AG
  • Yunnan Baiyao Group Co., Ltd.

You can easily book an appointment with one online.

  • Musculoskeletal Disorder
  • United States
  • Asterias Biotherapeutics, Inc.
  • BioTime, Inc.
  • OrthoCyte Corporation
  • 7.1 BIBLIOGRAPHY

Epidemiology of rheumatic musculoskeletal disorders in the developing world.

  • Musculoskeletal Disorder
  • Market Size
  • Beckman Coulter, Inc.
  • F. Hoffmann-La Roche Ltd.
  • SQI Diagnostics Inc.
  • 4.1 BIBLIOGRAPHY

BMC Musculoskeletal Disorders; ##(##): ##.

  • Musculoskeletal Disorder
  • Japan
  • Spain
  • United States
  • Forecast
  • Osteoporosis Therapeutics Market, Global, All Pipeline Products, Discovery,

Therapeutic Advances in Musculoskeletal Disease; ##(##): ##-## Masi L, et al. (2008).

  • Musculoskeletal Disorder
  • Market Size
  • Amgen Inc.
  • Merck & Co., Inc.
  • Uni-Bio Science Group Limited
  • 7.2 MUSCULOSKELETAL DISORDERS
  • MUSCULOSKELETAL DISORDERS TO DOMINATE THE REGENERATIVE MEDICINE

REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2017-2024 (USD BILLION) ##. ##. ## In 2018, North America accounted for the largest share of the regenerative medicine market for musculoskeletal disorders.

  • Cell Therapy
  • Musculoskeletal Disorder
  • North America
  • United States
  • Novartis AG
  • PROPORTION OF DEGENERATIVE SPONDYLOLISTHESIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2019*
  • PROPORTION OF DEGENERATIVE SPONDYLOLISTHESIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2019*

PROPORTION OF DEGENERATIVE SPONDYLOLISTHESIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2019* PROPORTION OF DEGENERATIVE SPONDYLOLISTHESIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2019* As of April 2019, there were ## cl

  • Clinical Trial
  • Musculoskeletal Disorder
  • World
  • Product Initiative
  • Mesoblast Limited
  • PROPORTION OF DERMATOMYOSITIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2019*
  • PROPORTION OF DERMATOMYOSITIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2019*

PROPORTION OF DERMATOMYOSITIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2019* PROPORTION OF DERMATOMYOSITIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2019* In total there were ## clinical trials conducted on Dermatomyosi

  • Medical Biotechnology
  • Musculoskeletal Disorder
  • Neurological Disorder
  • World
  • Product Initiative
  • PROPORTION OF DEGENERATIVE SCOLIOSIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2019*
  • PROPORTION OF DEGENERATIVE SCOLIOSIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2019*

PROPORTION OF DEGENERATIVE SCOLIOSIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2019* PROPORTION OF DEGENERATIVE SCOLIOSIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2019* CLINICAL TRIALS IN E## COUNTRIES BY TRIAL STATUS As

  • Chronic Disease
  • Musculoskeletal Disorder
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF ARTHRALGIA TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF ARTHRALGIA TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS

PROPORTION OF ARTHRALGIA TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF ARTHRALGIA TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* In total there were ## clinical trials conducted on Arthralgia, as of Nove

  • Clinical Trial
  • Musculoskeletal Disorder
  • Therapy
  • World
  • Product Initiative
  • Proportion of Cachexia to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2016*
  • Proportion of Cachexia to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2016*

PROPORTION OF CACHEXIA TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF CACHEXIA TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF CACHEXIA TO MUSCULOSKELETAL DISORDERS CLINICAL

  • Clinical Trial
  • Drug Development
  • Musculoskeletal Disorder
  • World
  • Product Initiative
  • PROPORTION OF ARTICULAR CARTILAGE DEFECT TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • Proportion of Articular Cartilage Defect to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2016*

PROPORTION OF ARTICULAR CARTILAGE DEFECT TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF ARTICULAR CARTILAGE DEFECT TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* In total there were ## clinical trials con

  • Cell Therapy
  • Musculoskeletal Disorder
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF ATROPHY TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF ATROPHY TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*

PROPORTION OF ATROPHY TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF ATROPHY TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* In total there were ## clinical trials conducted on Atrophy, as of November 2018

  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF BONE DEGENERATION TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF BONE DEGENERATION TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*

PROPORTION OF BONE DEGENERATION TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF BONE DEGENERATION TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* In total there were ## clinical trials conducted on Bone Deg

  • Musculoskeletal Disorder
  • Therapy
  • World
  • Product Initiative
  • Novartis AG
  • PROPORTION OF BONE DEFECTS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF BONE DEFECTS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*

PROPORTION OF BONE DEFECTS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF BONE DEFECTS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* In total there were ## clinical trials conducted on Bone Defects, as o

  • Clinical Trial
  • Drug Development
  • Musculoskeletal Disorder
  • World
  • Product Initiative
  • REFERENCES

Prevalence and impact of musculoskeletal disorders of the upper limb in the general population.

  • Arthritis
  • Chronic Disease
  • Epidemiology
  • Musculoskeletal Disorder
  • Forecast
  • PROPORTION OF AXIAL SPONDYLOARTHRITIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF AXIAL SPONDYLOARTHRITIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF AXIAL SPONDYLOARTHRITIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF AXIAL SPONDYLOARTHRITIS TO MUSCULOSKELETAL DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* In total there were ## clinical trials conducted

  • Musculoskeletal Disorder
  • Therapy
  • World
  • Product Initiative
  • UCB S.A.